Provided by Tiger Fintech (Singapore) Pte. Ltd.

NovoCure

12.43
+0.52004.37%
Post-market: 12.42-0.0100-0.08%19:55 EDT
Volume:1.44M
Turnover:17.76M
Market Cap:1.39B
PE:-7.97
High:12.47
Open:12.08
Low:11.96
Close:11.91
52wk High:34.13
52wk Low:10.87
Shares:111.80M
Float Shares:94.15M
Volume Ratio:1.24
T/O Rate:1.53%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.5604
EPS(LYR):-1.5638
ROE:-48.07%
ROA:-8.64%
PB:3.98
PE(LYR):-7.95

Loading ...

Novocure Submits Premarket Approval Application to FDA for Tumor Treating Fields Therapy in Pancreatic Cancer, Decision Anticipated in Second Half of 2026

Reuters
·
Aug 20

Novocure Submits Premarket Approval Application to FDA for Tumor Treating Fields Therapy in Locally Advanced Pancreatic Cancer

THOMSON REUTERS
·
Aug 20

Novocure Ltd: Anticipates an Approval Decision in Second Half of 2026

THOMSON REUTERS
·
Aug 20

Stock Track | NovoCure Soars 6.18% Following CFO's Major Stock Purchase

Stock Track
·
Jul 31

Stock Track | NovoCure Surges 5.65% Pre-market Following CFO's Major Stock Purchase

Stock Track
·
Jul 31

NovoCure’s CFO Makes a Bold Move with Major Stock Purchase

TIPRANKS
·
Jul 31

Christoph Brackmann, CFO, Reports Acquisition of Common Shares in Novocure Ltd

Reuters
·
Jul 31

Why NovoCure Stock Is Cratering Today

Motley Fool
·
Jul 30

Novocure’s Earnings Call: Clinical Successes & Cautious Optimism

TIPRANKS
·
Jul 29

NovoCure Shares Fall After Wells Fargo Downgrade

MT Newswires Live
·
Jul 26

Stock Track | NovoCure Plummets 5.18% as Wells Fargo Downgrades Stock and Slashes Price Target

Stock Track
·
Jul 25

Novocure Ltd. Reports Q2 2025 Financial Results

TIPRANKS
·
Jul 25

NovoCure Q2 Revenue Jumps 6 Percent

Motley Fool
·
Jul 25

Stock Track | NovoCure Plummets 24% After Q2 Results Show Widening Losses Despite Revenue Growth

Stock Track
·
Jul 25

Novocure downgraded to Equal Weight from Overweight at Wells Fargo

TIPRANKS
·
Jul 25

Wedbush Cuts Price Target on NovoCure to $18 From $27, Maintains Neutral Rating

MT Newswires Live
·
Jul 25

BUZZ-U.S. STOCKS ON THE MOVE-Eaton, Karman, Mobileye Global

Reuters
·
Jul 25

NovoCure Down Nearly 16%, on Pace for Largest Percent Decrease Since August 2023 -- Data Talk

Dow Jones
·
Jul 25

NovoCure’s Strategic Growth and Market Expansion Drive Buy Rating

TIPRANKS
·
Jul 24

BUZZ-U.S. STOCKS ON THE MOVE-Labcorp, Blackstone, L3Harris

Reuters
·
Jul 24